Back to search
FDAFDA · Food and drugs·Recall number D-1130-2018

Valsartan Tablets, USP 40 mg Rx Only NDC 50268-783-15 50 Tablets (5x10) Unit Dose Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Published September 5, 2018 · Recall initiated: August 14, 2018

Summary

FDA records drug Class II recall D-1130-2018, published September 5, 2018 and initiated August 14, 2018. Recalling firm: AVKARE Inc.; Status: Terminated; Reported quantity: 6776 cartons (338,800 tablets); Lot: Lots: 18491 Exp. 10/2018; 19531 Exp. 04/2019; 20168 Exp. 05/2019; 20671 Exp. 08/2019; 21049 Exp. 10/2019; 21635 Exp. 10/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
AVKARE Inc.
Distributor
U.S. Nationwide
Lot
Lots: 18491 Exp. 10/2018; 19531 Exp. 04/2019; 20168 Exp. 05/2019; 20671 Exp. 08/2019; 21049 Exp. 10/2019; 21635 Exp. 10/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Valsartan Tablets, USP 40 mg Rx Only NDC 50268-783-15 50 Tablets (5x10) Unit Dose Manufactured for: AvKARE, Inc. Pulaski, TN 38478 recalled?

Yes. FDA published recall D-1130-2018 on September 5, 2018. Reported hazard: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter